Lexicon Pharmaceuticals Stock News

The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. The post 7 Biotech Stocks With Key Catalysts for May appeared first on Investo

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q1 2022 Results Conference Call May 5, 2022 8:00 AM ET Company Participants Charles Schultz - Investor Relations Lonnel Coats - President and Chief Executi

THE WOODLANDS, Texas, April 29, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2022 financial results on Thursday, May 5, 2022 before the markets

Late-breaking clinical trial presentation by Deepak L. Bhatt, M.D., M.P.H., will describe new analysis of rates of CV death, myocardial infarction and stroke in the SCORED trial Late-breaking clinical

THE WOODLANDS, Texas, March 17, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it entered into a loan facility with Oxford Finance LLC that provides up to $150

During the last session, Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX)’s traded shares were 0.65 million, with the beta value of the company hitting 1.54. At the end of the trading day, the stock’s price was $2.09, reflecting an intraday loss of -1.88% or -$0.04. The 52-week high for the LXRX share is $7.39, that puts it down … Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX)’s -1.88% Loss This Week Just Tells Us Something New Read More »

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) (NASDAQ: LXRX) investors concerning the Company’s possible violations of the federal securities laws. If you suffered a loss on your Lexicon investments or would like to inquire about potentially pursuing claims to recover your loss under the federal se

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) (NASDAQ: LXRX) investors concerning the Company’s possible violations of federal securities laws. On February 28, 2022, Lexicon issued a press release announcing the voluntary withdrawal of the Company’s New Drug Application for its glucose regulation drug, sotagliflozin, in order to correct a technical issue with the submission that h

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) (NASDAQ: LXRX) on behalf of investors concerning the Company’s possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 28, 2022, Lexicon issued a press release announcing the voluntary withdrawal of the Company’s New Drug Application for its glucose regulation drug, sot

Moderna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals have been highlighted in this Analyst Blog.

Updates from Moderna (MRNA) and Kodiak Sciences Inc (KOD) are a few key highlights from the biotech sector during the past week.

NEW YORK, March 2, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lexicon Pharmaceuticals, Inc. ("Lexicon" or the "Company") (NASDAQ: LXRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980….

The shares are reeling from disquieting news about the company's leading pipeline drug.

The shares are reeling from disquieting news about the company''s leading pipeline drug.

The shares are reeling from disquieting news about the company's leading pipeline drug.